Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca Arimidex

Executive Summary

Anastrozole tablets receive FDA approval Sept. 1 for first-line treatment of postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer. AstraZeneca has committed to submit annual safety and survival updates for its pivotal studies until 75% of patients are deceased. Arimidex was previously approved for use following patient failure on AstraZeneca's Nolvadex. The first-line indication will allow AstraZeneca to complement Nolvadex, which saw a sales decline of 5% in the first half

You may also be interested in...

Femara First-Line Breast Cancer Label Includes Tamoxifen Superiority Claim

Novartis' Femara (letrozole) first-line breast cancer approval Jan. 10 is based on superiority over tamoxifen (AstraZeneca's Nolvadex and Barr's generic).

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts